Acquired resistance to third-generation EGFR-TKIs and emerging next-generation EGFR inhibitors

The discovery that mutations in the EGFR gene are detected in up to 50% of lung adenocarcinoma patients, along with the development of highly efficacious epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), has revolutionized the treatment of this frequently occurring lung mali...

Descripción completa

Detalles Bibliográficos
Autores principales: Du, Xiaojing, Yang, Biwei, An, Quanlin, Assaraf, Yehuda G., Cao, Xin, Xia, Jinglin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8454558/
https://www.ncbi.nlm.nih.gov/pubmed/34557754
http://dx.doi.org/10.1016/j.xinn.2021.100103

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8454558/
https://www.ncbi.nlm.nih.gov/pubmed/34557754
http://dx.doi.org/10.1016/j.xinn.2021.100103

Ejemplares similares